Novartis Sues India's Cipla Over Respiratory Drug

Dec 18, 2014

Reuters

Novartis has sued India's Cipla for infringing patents on respiratory drug Onbrez, after Cipla launched a generic In New Delhi in October.

Cipla claimed an "urgent unmet need" for the drug in India, however Novartis claims there is no shortage of Onbrez.

Onbrez is used to treat chronic obstructive pulmonary disease, and has patent protection until 2020. Novartis said it had planned to partner with generic drugmaker Lupin to sell the drug in India.

Read the Reuters article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments